Tumor DNA sequencing in MBC is currently not yet common in clinical practice and is mostly reserved for the determination of the mutational status of the BRCA1/BRCA2, PIK3CA, and, more rarely, the ESR1 and ERBB2 genes [5,6]. This evidence concerns the gene BRCA2 and neoplasm.